Real-World Antibiotic Strategies for Multidrug-Resistant Pseudomonas aeruginosa: Evidence from the Italian SUSANA Multicentre Study
Authors:
- Francesca GavaruzziFGFrancesca Gavaruzzi
- Giordano MadedduGiordano Madeddu
- Elena Delfina RicciERElena Delfina Ricci
- Matteo FaltoniMFMatteo Faltoni
- Alessandra BanderaABAlessandra Bandera
- Francesca ColucciFCFrancesca Colucci
- Andrea De VitoAVAndrea De Vito
- Angelo MaccaroAMAngelo Maccaro
- Paolo MaggiPMPaolo Maggi
- Stefania PiconiSPStefania Piconi
- Giovanni CenderelloGCGiovanni Cenderello
- Marco MerliMMMarco Merli
Open Access
- 17 August 2026
- journal article
- research article
- Published by MDPI AG in Antibiotics
- Vol. 15 (8) , 796
Abstract
Background/Objectives: Multidrug-resistant (MDR) Pseudomonas aeruginosa pneumonia and bloodstream infections (BSI) remain challenging because of their severity, limited therapeutic options, and high mortality, despite the availability of novel β-lactam-based agents. We aimed to describe real-world treatment patterns, characteristics associated with treatment and infusion-strategy selection, and the association of these strategies with clinical outcomes in the retrospective, multicentre Italian SUSANA cohort, an observational study evaluating the use, safety, and outcomes of novel antibiotics in hospitalized patients. Methods: Adults with MDR P. aeruginosa pneumonia and/or BSI treated with novel antipseudomonal agents for ≥72 h were included. Treatment was classified as monotherapy or combination therapy, and infusion strategy as prolonged/continuous or standard. The primary outcome was 28-day all-cause mortality. A multivariable Cox regression analysis was performed. Results: Among 173 patients, pneumonia was the most frequent clinical presentation (74.0%). Monotherapy was used in 111 patients (64.2%), combination therapy in 62 (35.8%), and prolonged/continuous infusion in 120 (69.4%). Ceftolozane–tazobactam (CT) (64.7%) and ceftazidime–avibactam (CZA) (20.2%) were the most prescribed agents. Patients receiving prolonged/continuous infusion, regardless of monotherapy or combination therapy, had greater baseline clinical severity than those receiving standard infusion. Overall, 28-day mortality was 23.7%. In the multivariable analysis, neither combination therapy nor prolonged/continuous infusion was independently associated with reduced mortality, whereas septic shock (aHR 4.10, 95% CI 1.01–16.66) and ICU admission (aHR 2.53, 95% CI 1.06–6.08) increased mortality risk. Conclusions: In this multicentre real-world cohort, treatment strategies for MDR P. aeruginosa pneumonia and BSI appeared to be influenced by baseline severity and patient-related factors. Mortality was more strongly associated with markers of severe illness, including ICU admission and septic shock. No independent association with improved survival was observed for combination therapy compared with monotherapy or for prolonged/continuous compared with standard infusion. These findings highlight the prognostic role of baseline clinical severity and support the need for prospective, randomized, pharmacokinetic/pharmacodynamic (PK/PD)-guided studies to identify patients who may benefit from these strategies.Keywords
This publication has 31 references indexed in Scilit:
- How do I manage difficult-to-treat Pseudomonas aeruginosa infections? Key questions for today’s cliniciansClinical Microbiology and Infection, 2025
- Continuous vs Intermittent β-Lactam Antibiotic Infusions in Critically Ill Patients With SepsisJAMA, 2024
- Prolonged vs Intermittent Infusions of β-Lactam Antibiotics in Adults With Sepsis or Septic ShockJAMA, 2024
- Extended-Infusion β-Lactam Therapy, Mortality, and Subsequent Antibiotic Resistance Among Hospitalized Adults With Gram-Negative Bloodstream InfectionsJAMA Network Open, 2024
- Novel β-lactam-β-lactamase inhibitors as monotherapy versus combination for the treatment of drug-resistant Pseudomonas aeruginosa infections: A multicenter cohort studyJournal of Infection and Chemotherapy, 2024
- Continuous vs Intermittent Meropenem Administration in Critically Ill Patients With SepsisJAMA, 2023
- European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)Clinical Microbiology and Infection, 2022
- Prolonged Versus Intermittent Infusion of β-Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection ModelsClinical Pharmacokinetics, 2020
- Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#Intensive Care Medicine, 2020
- Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosaEuropean Journal of Clinical Microbiology & Infectious Diseases, 2019